Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 447 participants.

Also called NCT01632163

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 447 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01632163
Other papers using this trial's data
  • Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial Diabetes, obesity & metabolism, 2018-02 DOI, PubMed 28742225, PMC5813270 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, India, Russia, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01632163. Randomized; triple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Placebo
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01632163
Content hash
6e305bf89e958d9f09e9d83bb65a4890ad79496355bce0fd6e6318f7cc578b7b